Evaluation of Community Pharmacists Management of patients with Acute exacerbations of Atopic Dermatitis (6 months to 65 years), Impetigo (12 months and above), Mild-Plaque Psoriasis and Herpes Zoster (18 years and above): PATH-DERM

开始日期2024-07-19

申办/合作机构

The University of Newcastle

[+5]

NCT05363397 / Recruiting临床2期IIT

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS.
Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, TBO-309, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.

开始日期2023-09-27

申办/合作机构

The George Institute for Global Health

[+1]

ACTRN12620000233921 / RecruitingN/AIIT

Determining the feasibility of opportunistic self-screening for atrial fibrillation in general practice among patients aged 65 years and older: Atrial Fibrillation Self-Screening, Management and Guideline Recommended Therapy (AF Self SMART)

开始日期2020-08-28

申办/合作机构

The University of Sydney

[+1]

100 项与 The Heart Research Institute Ltd. 相关的临床结果

登录后查看更多信息

0 项与 The Heart Research Institute Ltd. 相关的专利（医药）

登录后查看更多信息

2,261

项与 The Heart Research Institute Ltd. 相关的文献（医药）

2024-10-01·EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY

Patient Factors Influencing Prescription of Antithrombotic Medication After Lower Limb Endovascular Intervention

Article

作者: Hajian, Hamid ; Zhu, Alison ; Aitken, Sarah ; Rajendran, Saissan

OBJECTIVE:

There is significant practice variation in the use of antithrombotic therapy after endovascular intervention for lower limb peripheral arterial disease, with differences in medication choice and duration. Prescriber decision making is complex, and patient factors have been shown to substantially contribute to prescribing variation. To determine the influence of patient factors on antithrombotic prescribing, a discrete choice experiment was distributed to vascular surgeons and trainees across Australia and Aotearoa New Zealand.

METHODS:

After pilot testing, the discrete choice experiment questionnaire was distributed to 300 vascular surgeons and trainee members of the Australian and New Zealand Society for Vascular Surgery. Multinomial logistic regression models were used to analyse patient factors that had the most influence on decisions to prescribe a second antithrombotic agent, and the preferred choice of antithrombotic (clopidogrel 75 mg daily or rivaroxaban 2.5 mg twice daily) in addition to aspirin 100 mg daily. The odds ratio (OR) with 95% confidence interval (CI) reported preference strength.

RESULTS:

A total of 44 questionnaires were completed between September and October 2023, reaching the 15% targeted response rate. Prescribing a second antithrombotic was more likely after femoropopliteal stenting compared with angioplasty (OR 1.89, 95% CI 1.20 - 2.13), and in chronic limb threatening ischaemia compared with intermittent claudication (OR 1.58, 95% CI 1.20 - 2.13). Most respondents preferred clopidogrel over rivaroxaban (62%), with over a third of respondents exclusively prescribing clopidogrel. Patients with stents (OR 1.77, 95% CI 1.32 - 2.37) or moderate bleeding risk (OR 1.38, 95% CI 0.97 - 1.84) were more likely to receive clopidogrel than rivaroxaban.

CONCLUSION:

This study demonstrates that vascular surgeons primarily prioritise antithrombotic prescribing decisions by procedure type. Clopidogrel is more likely to be prescribed than rivaroxaban as a second agent in combination with aspirin, especially after stenting. Knowing these clinician preferences can target implementation strategies towards supporting decision making in subgroups of patients according to individual risk profiles.

2024-10-01·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.

Article

作者: Ezekowitz, Justin A ; Kosiborod, Mikhail N ; Coats, Andrew J S ; Lund, Lars H ; Butler, Javed ; Belohlavek, Jan ; Anker, Stefan D ; Pitt, Bertram ; Weir, Matthew R ; Ponikowski, Piotr ; Bayes-Genis, Antoni ; Böhm, Michael ; van der Meer, Peter ; Waechter, Sandra ; Piña, Ileana L ; Brugts, Jasper J ; Friede, Tim ; Budden, Jeffrey ; Mentz, Robert J ; Perrin, Amandine ; Senni, Michele ; Bahit, Cecilia ; Filippatos, Gerasimos ; Rossignol, Patrick ; Pinto, Fausto J ; Metra, Marco

BACKGROUND:

Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF).

OBJECTIVES:

This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) run-in phase.

METHODS:

Patients with HFrEF and HK or past HK entered a run-in phase of ≤12 weeks with patiromer-facilitated RAS inhibitor/MRA optimization to achieve ≥50% recommended RAS inhibitor dose, 50 mg/d MRA, and normokalemia. Patients achieving these criteria (randomized group) were compared with the run-in failure group (patients not meeting the randomization criteria).

RESULTS:

Of 1,038 patients completing the run-in, 878 (84.6%) were randomized and 160 (15.4%) were run-in failures. Overall, 422 (40.7%) had HK entering run-in with a similar frequency in the randomized and run-in failure groups (40.3% vs 42.5%; P = 0.605). From start to the end of run-in, in the randomized group, an increase was observed in target RAS inhibitor and MRA use in patients with HK (RAS inhibitor: 76.8% to 98.6%; MRA: 35.9% to 98.6%) and past HK (RAS inhibitor: 60.5% to 98.1%; MRA: 15.6% to 98.7%). Despite not meeting the randomization criteria, an increase after run-in was observed in the run-in failure group in target RAS inhibitor (52.5% to 70.6%) and MRA use (15.0% to 48.1%). This increase was observed in patients with HK (RAS inhibitor: 51.5% to 64.7%; MRA: 19.1% to 39.7%) and past HK (RAS inhibitor: 53.3% to 75.0%; MRA: 12.0% to 54.3%).

CONCLUSIONS:

In patients with HFrEF and HK or past HK receiving suboptimal RAS inhibitor/MRA therapy, RAS inhibitor/MRA optimization increased during patiromer-facilitated run-in.

2024-09-03·Journal of the American Heart Association

Percentage Predicted Peak Oxygen Consumption in People With Fontan Circulation: A Rapid Systematic Scoping Review and Validation Study

Review

作者: Cordina, Rachael ; Tomlinson, Owen W. ; Ayer, Julian ; Stuart, A. Graham ; Weintraub, Robert G. ; Barker, Alan R. ; Tran, Derek L. ; Laohachai, Karina ; Williams, Craig A. ; Wadey, Curtis A.

Background:

Peak oxygen consumption (peak V̇O2$$ \dot{\mathrm{V}}{\mathrm{O}}_2 $$ ) is routinely measured in people who have congenital heart disease and is reported as a percentage of predicted value, based upon age‐ and sex‐matched normative reference values (NRVs). This study aimed to identify which NRVs are being used, assess whether NRVs are being applied appropriately, and evaluate if recommended NRVs are valid when applied to people with congenital heart disease.

Methods and Results:

A systematic scoping review identified studies that reported peak V̇O2$$ \dot{\mathrm{V}}{\mathrm{O}}_2 $$ percentage of predicted value in people with congenital heart disease. A modified risk of bias tool evaluated the included studies. Forty‐five studies reported peak V̇O2$$ \dot{\mathrm{V}}{\mathrm{O}}_2 $$ percentage of predicted value, and only 21 (47%) studies described or provided a reference on how their percentage of predicted value was calculated. The most cited NRVs were from Wasserman (n=12) and Cooper and Weiler‐Ravell (n=7). Risk of bias analysis judged 63% of studies as having some concerns. The NRVs recommended by the American Heart Association were applied to participants with a Fontan circulation (n=70; aged 26.5±6.4 years; 59% women) to examine validity. Predicted peak V̇O2$$ \dot{\mathrm{V}}{\mathrm{O}}_2 $$ values from the Wasserman NRV was not significantly associated to measured peak V̇O2$$ \dot{\mathrm{V}}{\mathrm{O}}_2 $$ values (men: b=0.31, R2 ≤0.01; women: b=0.07, R2 =0.02).

Conclusions:

Numerous NRVs have been applied to individuals with congenital heart disease and are often poorly reported and inappropriately matched to participants. The Wasserman NRV was the most cited but showed poor validity when applied to a Fontan cohort.

项与 The Heart Research Institute Ltd. 相关的新闻（医药）

2023-08-29

·PRNewswire

For Realizing Vision of ZERO Cerebro-Cardiovascular Events, OMRON Healthcare Sponsors First Annual Meeting of AF Screen International Collaboration

KYOTO, Japan, Aug. 29, 2023 /PRNewswire/ -- OMRON Healthcare Co., Ltd. (hereinafter referred to as the Company) based in Muko, Kyoto Prefecture, has announced the official sponsorship of the first annual meeting of the AF Screen International Collaboration, a collaborative group that was established to promote discussion and research about screening for unknown or under-treated atrial fibrillation (AF) as a way to reduce stroke and death. Logo: A World Health Organization (WHO) report shows that the global leading cause of death is heart disease, followed by stroke. The number of cerebrovascular and cardiovascular diseases continues to rise due to the accelerating aging of the population and lifestyle changes caused by economic growth. As the Company believes the early detection of AF is a key to solve these health-related challenges, it has dedicated to communicating the importance of blood pressure control by using a home blood pressure monitor with a wider audience. In 2020, "Complete (TM)," an upper-arm blood pressure monitor with built-in ECG technology, was released and at the same time, the Company launched a couple of initiatives by using home ECG monitors for detecting AF at an early stage. In addition, the OMRON Academy, a learning program for healthcare professionals, has been actively implemented to raise awareness of the disease. The AF Screen International Collaboration is a research group that consists of more than 200 members from 40 countries led by globally notable professionals such as Professor Ben Freedman of the University of Sydney. It has committed to disease awareness activities aimed at early detection of AF, and the advocacy for implementation of AF screening programs, tailored to the medical systems of individual countries. The Company sponsored the first annual meeting of the AF Screen International Collaboration, and during the meeting, physicians presented the latest findings in early detection of AF as well as the risk of developing AF in hypertensive patients and agreed to jointly conduct future disease awareness activities. For realizing the vision of Going for ZERO, achieving zero cerebro-cardiovascular events, the Company has committed to supporting a better hypertension treatment and early detection of AF in collaboration with healthcare professionals and researchers. - Annual meeting of AF Screen International Collaboration Date: Thursday, August 24, 2023 (CEST) Venue: Hilton Amsterdam Airport Schiphol *The AF screening conference is organized on behalf of the AF Screen International Collaboration by the Translational Medicine Academy (TMA), a non-profit foundation based in Switzerland () Organizer: Prof. Ben Freedman Director External Affairs at the Heart Research Institute, Charles Perkins Centre and Group Leader of the Heart Rhythm and Stroke Prevention Group. Professor of Cardiology at the University of Sydney and former head of the Department of Cardiology, Concord Hospital. Program: - Early AF detection and outcomes other than stroke - AF-SCREEN Year in review - Hypertension and AF - Combined Hypertension + AF White paper - UPDATE on continuing screening RCTs and IP SOURCE OMRON Healthcare Co., Ltd.

AHA会议

100 项与 The Heart Research Institute Ltd. 相关的药物交易

登录后查看更多信息

100 项与 The Heart Research Institute Ltd. 相关的转化医学

登录后查看更多信息